Abstract
Increases in the level of cyclooxygenase (COX)-2 and prostanoids such as prostaglandin E(2) (PGE(2)) are considered biomarkers of colorectal cancer. Therefore, non-steroidal anti-inflammatory drugs (NSAID) have been used to reduce the risk of cancer development by reducing prostanoid biosynthesis as COX inhibitors. Along with their activity as COX inhibitors, NSAID have been reported to have other effects. One major NSAID, indomethacin, has been shown to have several effects independent of COX inhibition. To further examine the COX-inhibition-independent effects of indomethacin on colorectal cancer, we used human colon cancer LS174T cells, known to have express little COX-2 and have no detectable PGE(2) production. Here we show that indomethacin has a potential antagonizing effect on human EP(2) receptors. We believe this study raises the reasons to use indomethacin as a lead-compound for setting up another EP(2) receptor-specific antagonist as a relatively cost-efficient strategy for anti-cancer medication in the future.
References
Jan 15, 2000·Biochimica Et Biophysica Acta·M AbramovitzK M Metters
Aug 10, 2000·The Journal of Biological Chemistry·J ShaoR N DuBois
Jan 5, 2001·British Journal of Pharmacology·D H WrightK M Metters
Oct 20, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·I TegederG Geisslinger
Nov 14, 2001·The Journal of Biological Chemistry·Hiromichi FujinoJohn W Regan
Jul 23, 2003·Trends in Pharmacological Sciences·Hiromichi Fujino, John W Regan
Aug 5, 2003·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Kinya Nagata, Hiroyuki Hirai
Nov 11, 2003·Life Sciences·John W Regan
Jan 31, 2004·Biochemical and Biophysical Research Communications·ShouWei Han, Jesse Roman
Jan 11, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jose U Scher, Michael H Pillinger
Apr 5, 2005·The Journal of Pharmacology and Experimental Therapeutics·Basil Rigas, Khosrow Kashfi
Jun 9, 2007·Biochemical and Biophysical Research Communications·Hiromichi FujinoToshihiko Murayama
Oct 19, 2007·Acta Oncologica·Annika GustafssonKent Lundholm
Nov 7, 2008·Journal of Pharmacological Sciences·Takashi OridoToshihiko Murayama
Jul 25, 2009·British Journal of Pharmacology·R L JonesD F Woodward
Dec 1, 2009·Archives of Biochemistry and Biophysics·Takashi OridoToshihiko Murayama
May 21, 2011·British Journal of Pharmacology·Mark A Birrell, Anthony T Nials
May 21, 2011·British Journal of Pharmacology·K J af ForsellesN Pullen
Aug 16, 2011·Biochemical Pharmacology·Tomoko KatoToshihiko Murayama
Citations
Nov 19, 2013·Archives of Biochemistry and Biophysics·Satomi OyamaToshihiko Murayama
Feb 8, 2013·Cell & Bioscience·Viola AllajDaotai Nie
Jan 9, 2017·Colloids and Surfaces. B, Biointerfaces·Abbas AkhgariAli Nokhodchi
Mar 28, 2017·International Journal of Pharmaceutics·Dong JiaGareth R Williams
Jul 14, 2017·Journal of Drug Targeting·Chao Chen, Binbin Wang
Jan 27, 2019·International Journal of Molecular Sciences·Miyu IshiiNoriaki Nagai
Oct 3, 2017·Biological & Pharmaceutical Bulletin·Naofumi SeiraHiromichi Fujino
Aug 11, 2018·Cancer Metastasis Reviews·Dali TongJun Jiang
May 19, 2019·Journal of Drug Targeting·Chen YangXiaole Qi
Jun 25, 2013·European Journal of Pharmacology·Tsukasa IshidaShigeto Mizuno